Selection of Treatment Strategy for Patients with Vaginal and Uterine Aplasia Combined with Ovarian-Origin Hyperandrogenism

Vaginal and uterine aplasia (Mayer–Rokitansky–Kuster–Hauser syndrome, MRKH) is one of the most complex anomalies in the development of the female reproductive system. It is characterized by the absence of the uterus and vagina in patients with a normal karyotype (46, XX) and preserved ovarian function [1, 2]. According to the literature, the incidence of this pathology ranges from 1:4000 to 1:5000 newborn girls; however, exact figures may vary depending on diagnostic methods and selection criteria [7, 10].